Outcome of Scapular Ewing Sarcoma.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 19 06 2022
revised: 28 06 2022
accepted: 30 06 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 30 7 2022
Statut: ppublish

Résumé

Ewing sarcoma is a common primary bone tumor, often located in the distal femur or pelvis. Although the scapula is a flat bone similar to the pelvis, scapular Ewing sarcoma is rare. The aim of this study was to review our institution's experience with the management of scapular Ewing sarcomas. We reviewed 9 patients with an Ewing sarcoma of the scapula, which included 5 males and 4 females with a mean age of 19±6 years. All patients were treated with chemotherapy and local control. Local control included surgical resection (n=7) and definitive radiotherapy (n=2). Mean follow-up was 6 years. Prior to induction chemotherapy, the mean tumor size and volume were 10±2 cm and 181±112 cm Scapular Ewing sarcoma is a rare, aggressive tumor. Even with chemotherapy and local control with surgery or definitive radiotherapy, patient survival is poor.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Ewing sarcoma is a common primary bone tumor, often located in the distal femur or pelvis. Although the scapula is a flat bone similar to the pelvis, scapular Ewing sarcoma is rare. The aim of this study was to review our institution's experience with the management of scapular Ewing sarcomas.
PATIENTS AND METHODS METHODS
We reviewed 9 patients with an Ewing sarcoma of the scapula, which included 5 males and 4 females with a mean age of 19±6 years. All patients were treated with chemotherapy and local control. Local control included surgical resection (n=7) and definitive radiotherapy (n=2). Mean follow-up was 6 years.
RESULTS RESULTS
Prior to induction chemotherapy, the mean tumor size and volume were 10±2 cm and 181±112 cm
CONCLUSION CONCLUSIONS
Scapular Ewing sarcoma is a rare, aggressive tumor. Even with chemotherapy and local control with surgery or definitive radiotherapy, patient survival is poor.

Identifiants

pubmed: 35896233
pii: 42/8/3869
doi: 10.21873/anticanres.15879
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

3869-3872

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

John B Hargiss (JB)

Alix School of Medicine, Mayo Clinic, Rochester, MN, U.S.A.

Joshua R Labott (JR)

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A.

Samuel E Broida (SE)

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A.

Peter S Rose (PS)

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A.

Johnathan D Barlow (JD)

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A.

Matthew T Houdek (MT)

Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, U.S.A. houdek.matthew@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH